Skip to main content
. Author manuscript; available in PMC: 2016 Dec 20.
Published in final edited form as: Sci China Life Sci. 2016 Feb 26;59(12):1270–1281. doi: 10.1007/s11427-015-4997-y

Table 1.

Treatment status at time of blood sampling of patients with NMOSD

Drugs Number of patients Treat time before sampling, median (range), month
No treatment 12 8 (3–48)
Rituximab 5 24 (18–28)
Azathioprine 33 20 (3–60)
Oral corticosteroids 50 18 (2–35)
Azathioprine, oral corticosteroids, 11 13 (4–38)
Hydroxychloroquine, Methotrexate 1 3
Cyclophosphamide 7 15 (8–26)
Methotrexate 5 11 (6–24)
bimonthly, intravenous immunoglobulin 1 12